Myeloid growth factors clinical practice guidelines in oncology Journal Article
| Authors: | Crawford, J.; Althaus, B.; Armitage, J.; Blayney, D. W.; Cataland, S.; Dale, D. C.; Demetri, G. D.; Foran, J.; Heaney, M. L.; Htoy, S.; Kloth, D. D.; Lyman, G. H.; Michaud, L.; Motl, S.; Vadhan-Raj, S.; Wong, M. K. |
| Article Title: | Myeloid growth factors clinical practice guidelines in oncology |
| Abstract: | Chemotherapy-induced neutropenia is the major dose-limiting toxicity of systemic cancer chemotherapy, associated with substantial morbidity, mortality, and cost. Although prophylactic colony-stimulating factors (CSFs), can reduce this complication, their routine use in all patients on myelosuppressive chemotherapy is prohibitively costly. Selective use in patients most at risk for neutropenia may enhance cost-effectiveness, but determining the actual risk is complicated by issues in reporting myelosuppression and dose intensity, among other factors. For this reason, NCCN experts developed these guidelines to assist practitioners in the appropriate prophylactic use of CSFs. © Journal of the National Comprehensive Cancer Network. |
| Keywords: | cancer chemotherapy; treatment outcome; prednisone; clinical trial; neutropenia; review; anamnesis; cisplatin; doxorubicin; dose response; drug efficacy; gemcitabine; paclitaxel; chemotherapy; cytarabine; rituximab; topotecan; cancer staging; antineoplastic agent; carboplatin; dacarbazine; unindexed drug; quality of life; ovary cancer; breast cancer; bone marrow suppression; etoposide; lung non small cell cancer; antineoplastic combined chemotherapy protocols; morbidity; risk factors; health survey; nccn clinical practice guidelines; cyclophosphamide; dexamethasone; vincristine; practice guideline; oncology; bladder cancer; risk factor; cancer mortality; chlormethine; ifosfamide; vinblastine; docetaxel; irinotecan; febrile neutropenia; fever; sarcoma; standard; cost effectiveness analysis; health care cost; lung small cell cancer; hospitalization; disease severity; nonhodgkin lymphoma; head and neck cancer; chemically induced disorder; prophylaxis; uterine cervix cancer; mitoxantrone; therapy delay; comorbidity; medical oncology; bleomycin; vindesine; medical literature; methylprednisolone; bone marrow cell; mesna; toxicity; navelbine; recombinant granulocyte colony stimulating factor; testis cancer; drug dose regimen; colony-stimulating factors; recombinant granulocyte macrophage colony stimulating factor; drug use; filgrastim; myeloid growth factors; colony stimulating factor; granulocyte macrophage colony-stimulating factors, recombinant |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 3 |
| Issue: | 4 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2005-07-01 |
| Start Page: | 540 |
| End Page: | 555 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 16038645 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 22" - "Export Date: 24 October 2012" - "Source: Scopus" |
